Child developmental outcomes in preschool children following antidepressant exposure in pregnancy

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 7, 2015, Pages 642-650

  Galbally, Megan ^a,b   Lewis, Andrew J ^c   Buist, Anne ^b  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Antidepressants; child development; maternal depression; pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTIONING PRESCHOOL; BODY EQUILIBRIUM; CASE CONTROL STUDY; CHILD; CHILD BEHAVIOR; CHILD BEHAVIOR CHECKLIST; CHILD DEVELOPMENT; CLINICAL ARTICLE; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MOTOR DEVELOPMENT; MOVEMENT ASSESSMENT BATTERY FOR CHILDREN; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; SCORING SYSTEM; WECHSLER INTELLIGENCE SCALE; CHEMICALLY INDUCED; DEPRESSION; DRUG EFFECTS; INTELLIGENCE TEST; MALE; PREGNANCY; PRENATAL EXPOSURE; PSYCHOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DEPRESSION; FEMALE; HUMANS; INTELLIGENCE TESTS; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES;

EID: 84937000806     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867415569800     Document Type: Article

References (40)

1. Achenbach TM, Ruffle TM, (2000) The Child Behavior Checklist and related forms for assessing behavioral/emotional problems and competencies. Pediatrics in Review 21: 265-271.
2. Andrade SE, Raebel MA, Brown J,. (2008) Use of antidepressant medications during pregnancy: a multisite study. American Journal of Obstetrics and Gynecology 198: 194.e191-195.
3. Beck AT, Steer RA, Carbin MG, (1988) Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review 8: 77-100.
4. Casper RC, Fleisher BE, Lee-Ancajas JC,. (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Journal of Pediatrics 142: 402-408.
5. Casper RC, Gilles AA, Fleisher BE,. (2011) Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 217: 211-219.
6. Cooper WO, Willy ME, Pont SJ,. (2007) Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology 196: 544.e541-545.
7. Einarson A, (2005) Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice. Journal of Obstetrics and Gynaecology Canada 27: 1019-1022.
8. Fischer EH, Dornelas EA, Goethe JW, (2001) Characteristics of people lost to attrition in psychiatric follow-up studies. Journal of Nervous and Mental Disease 189: 49-55.
9. Galbally M, Lewis AJ, Buist A, (2011) Developmental outcomes of children exposed to antidepressants in pregnancy. Australian and New Zealand Journal of Psychiatry 45: 393-399.
10. Galbally M, Lewis AJ, Gentile S,. (2012) The biology of fetal exposure to serotonin reuptake inhibitors: implications for neurodevelopment. In: Migne LJ, Post JW, (eds) Antidepressants: Pharmacology, Health Effects and Controversy. New York: Nova, pp. 1-26.
11. Galbally M, Lewis AJ, Lum J,. (2009) Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Australian and New Zealand Journal of Psychiatry 43: 846-854.
12. Gentile S, Galbally M, (2010) Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. Journal of Affective Disorders 128: 1-9.
13. Grigoriadis S, VonderPorten EH, Mamisashvili L,. (2013) The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. Journal of Clinical Psychiatry 74: e309-320.
14. Gustavson K, von Soest T, Karevold E,. (2012) Attrition and generalizability in longitudinal studies: findings from a 15-year population-based study and a Monte Carlo simulation study. BMC Public Health 12: 918.
15. Hanley GE, Brain U, Oberlander TF, (2013) Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Human Development 89: 519-524.
16. Henderson SE, Sugden DA, Barnett AL,. (1992) Movement Assessment Battery for Children: Manual. London: The Psychological Corporation.
17. Isquith PK, Crawford JS, Espy KA,. (2005) Assessment of executive function in preschool-aged children. Mental Retardation and Developmental Disabilities Research Reviews 11: 209-215.
18. Jimenez-Solem E, Andersen JT, Petersen M,. (2013) Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 8: e63034.
19. Klinger G, Frankenthal D, Merlob P,. (2011) Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Journal of Perinatology 31: 615-620.
20. Lee HJ, Kim JW, Yim SV,. (2001) Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Molecular Psychiatry 6: 610, 725-728.
21. Lewis A, Galbally M, Bailey C, (2012) Perinatal mental health, antidepressants and neonatal outcomes: findings from the Longitudinal Study of Australian Children. Neonatal, Paediatric and Child Health Nursing 15: 22-28.
22. Lewis AJ, Galbally M, Gannon T,. (2014) Early life programming as a target for prevention of child and adolescent mental disorders. BMC Medicine 12: 33.
23. Lewis AJ, Galbally M, Opie G,. (2010) Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Australian and New Zealand Journal of Psychiatry 44: 482-487.
24. Mattson S, Eastvold A, Jones K,. (1999) Neurobehavioral follow-up of children prenatally exposed to fluoxetine. Teratology 59: 2.
25. Mayes LC, Ward A, (2003) Principles of neurobehavioral teratology. In: Cicchetti D, Walker E, (eds) Neurodevelopmental Mechanisms in Psychopathology. Cambridge: Cambridge University Press. pp. 3-33.
26. Misri S, Reebye P, Kendrick K,. (2006) Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. American Journal of Psychiatry 163: 1026-1032.
27. Mortensen J, Olsen J, Larsen H,. (2003) Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. European Journal of Epidemiology 18: 769-771.
28. Nulman I, Koren G, Rovet J,. (2012) Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. American Journal of Psychiatry 169: 1165-1174.
29. Nulman I, Rovet J, Stewart DE,. (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine 336: 258-262.
30. Nulman I, Rovet J, Stewart DE,. (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. American Journal of Psychiatry 159: 1889-1895.
31. Oberlander TF, Papsdorf M, Brain UM,. (2010) Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Archives of Pediatrics and Adolescent Medicine 164: 444-451.
32. Oberlander TF, Reebye P, Misri S,. (2007) Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Archives of Pediatrics & Adolescent Medicine 161: 22-29.
33. O'Connor TG, Heron J, Glover V, (2002) Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. Journal of the American Academy of Child and Adolescent Psychiatry 41: 1470-1477.
34. Pawluski JL, Rayen I, Niessen NA,. (2012) Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 220: 131-141.
35. Rayen I, van den Hove DL, Prickaerts J,. (2011) Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One 6: e24003.
36. Ross LE, Grigoriadis S, Mamisashvili L,. (2013) Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 70: 436-443.
37. Tambs K, Ronning T, Prescott CA,. (2009) The Norwegian Institute of Public Health twin study of mental health: examining recruitment and attrition bias. Twin Research and Human Genetics 12: 158-168.
38. Ververs T, Kaasenbrood H, Visser G,. (2006) Prevalence and patterns of antidepressant drug use during pregnancy. European Journal of Clinical Pharmacology 62: 863-870.
39. Weikum WM, Oberlander TF, Hensch TK,. (2012) Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proceedings of the National Academy of Sciences of the United States of America 109 Suppl 2: 17,221-17,227.
40. Zelazo PD, Carlson SM, Kesek A, (2008) The development of executive function in childhood. In: Nelson CA, Luciana M, (eds) Handbook of Developmental Cognitive Neuroscience, second edition. Cambridge, MA: The MIT Press.